ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.984,61
0,87%
S&P 500
5.477,01
0,30%
US Dollar vs BRL
5,6108
0,31%
Bitcoin
63.678,91
1,72%
Brent Oil
86,485
1,62%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vicuron Pharmaceuticals (MM) (MICU)

  7. Vicuron Pharmaceuticals (MM) (MICU) Notícias

MICU

Vicuron (MICU)

Vicuron Pharmaceuticals (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MICU
DataHoraFonteTítuloCódigoCompanhia
14/09/200505:00PR Newswire (US)Pfizer Completes Acquisition of Vicuron PharmaceuticalsNASDAQ:MICU
11/09/200514:00PR Newswire (US)Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for AcquisitionNASDAQ:MICU
18/08/200518:30PR Newswire (US)Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/CandidemiaNASDAQ:MICU
15/08/200518:30PR Newswire (US)Vicuron Pharmaceuticals Stockholders Approve Merger With PfizerNASDAQ:MICU
04/08/200518:30PR Newswire (US)Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial ResultsNASDAQ:MICUVicuron Pharmaceuticals (MM)
16/06/200503:00PR Newswire (US)Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-InfectivesNASDAQ:MICUVicuron Pharmaceuticals (MM)
02/06/200504:00PR Newswire (US)Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark OfficeNASDAQ:MICU
31/05/200504:00PR Newswire (US)Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal CandidiasisNASDAQ:MICU
26/05/200518:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific GrowthNASDAQ:MICU
17/05/200518:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech ConferenceNASDAQ:MICU
11/05/200504:00PR Newswire (US)Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug ApplicationNASDAQ:MICU
09/05/200518:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities HealthcareNASDAQ:MICU
05/05/200518:30PR Newswire (US)Vicuron Pharmaceuticals Announces First Quarter 2005 Financial ResultsNASDAQ:MICU
28/04/200509:30PR Newswire (US)Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged ConferenceNASDAQ:MICU
30/03/200519:30PR Newswire (US)Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community MarketNASDAQ:MICU
10/03/200518:30PR Newswire (US)Vicuron Pharmaceuticals Announces Fourth Quarter 2004 Financial ResultsNASDAQ:MICU
10/03/200509:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Health Care ConferenceNASDAQ:MICU
04/03/200504:00PR Newswire (US)Vicuron Pharmaceuticals Provides Update on Novartis Peptide Deformylase Inhibitor ProgramNASDAQ:MICU
25/02/200509:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare ConferenceNASDAQ:MICU
24/02/200504:00PR Newswire (US)Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue InfectionsNASDAQ:MICU
17/02/200510:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005NASDAQ:MICU
07/02/200505:00PR Newswire (US)Vicuron Pharmaceuticals Announces Phase 3 Trial Results Demonstrate Superiority of Anidulafungin Versus Fluconazole in InvasiveNASDAQ:MICU
24/01/200505:00PR Newswire (US)Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical OfficerNASDAQ:MICU
05/01/200510:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare ConferenceNASDAQ:MICU
21/12/200419:30PR Newswire (US)Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug AdministrationNASDAQ:MICU
29/11/200410:30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare ConferenceNASDAQ:MICU
04/11/200419:30PR Newswire (US)Vicuron Pharmaceuticals Announces Third Quarter 2004 Financial ResultsNASDAQ:MICU
01/11/200404:00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Supporting Next-Generation Lincosamide ProgramNASDAQ:MICU
01/11/200404:00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Demonstrating Potency of Anidulafungin and DalbavancinNASDAQ:MICU
25/10/200409:30PR Newswire (US)Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage ProductsNASDAQ:MICU
 Apresentando as notícias mais relevantes sobre:NASDAQ:MICU

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
OIBR3
OI ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
HAGA3
HAGA ON
BOV
GFSA3
GAFISA ON
BOV
BAZA3
AMAZONIA ON
BOV
PRIO3
PETRORIO ON
BOV
SEQL3
Sequoia Logistica e Tran... ON
BOV
IDIV
Dividend
BOV
COGN3
COGNA ON
BOV
CXSE3
Caixa Seguridade Partici... ON
BOV
CPLE6
COPEL PNB
BOV
RCSL4
RECRUSUL PN
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados